Working… Menu
Trial record 25 of 396 for:    LIRAGLUTIDE

Liraglutide Use in Prader-Willi Syndrome

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01542242
Recruitment Status : Terminated (Subject withdrew)
First Posted : March 2, 2012
Last Update Posted : December 9, 2015
Novo Nordisk A/S
Information provided by (Responsible Party):
David E. Harris, MD, Vancouver General Hospital

Brief Summary:

Liraglutide is a glucagon like peptide -1 (GLP-1) agonist, which is approved for use in patients with type 2 diabetes. Studies of liraglutide have shown an appetite suppressive effect and has been associated with weight loss in patients with type 2 diabetes. Liraglutide use in the treatment of PWS is limited to one case report by Cyganek et el (See attached Citation). In this case report, the subject showed improvements in hemoglobin A1c and body weight over 14 weeks.

The investigators plan to examine the use of liraglutide in a single subject with Prader Willi Syndrome and type 2 diabetes for one year. The investigators will examine clinical parameters, clinical assessment of hunger, and biochemical markers of diabetes and lipid control.

Condition or disease Intervention/treatment Phase
Diabetes Mellitus Type 2 Prader Willi Syndrome Drug: Liraglutide Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Study Start Date : February 2012
Actual Primary Completion Date : March 2013
Actual Study Completion Date : March 2013

Arm Intervention/treatment
Experimental: Liraglutide
Treatment of Diabetes Mellitus Type 2 with Liraglutide in the setting of Prader Willi Syndrome
Drug: Liraglutide
Liraglutide 0.6 mg SQ daily for one week, increase to a maximum dose of 1.8 mg SQ daily by 6 weeks, and subsequent continuation for the remainder of a year.
Other Name: Victoza

Primary Outcome Measures :
  1. Hemoglobin A1C [ Time Frame: Change from baseline in A1C at 12 months ]

Secondary Outcome Measures :
  1. Fasting Blood Glucose (mmol/L) [ Time Frame: Change from baseline in fasting blood glucose at 12 months ]
  2. Fasting Blood Insulin level [ Time Frame: Change from baseline in fasting blood insulin at 12 months ]
  3. Body Weight (kg) [ Time Frame: Change from baseline in body weight at 12 months ]
  4. Fasting Lipid Profile [ Time Frame: Change from baseline in fasting lipid profile at 12 months ]
  5. Hip Circumference (cm) [ Time Frame: Change from baseline in hip circumference at 12 months ]
  6. Total Body Adipose Tissue Distribution (whole body Computed Tomography) [ Time Frame: Change from baseline in total body adipose tissue distribution at 12 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   19 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Prader Willi Syndrome, Diabetes Type 2

Exclusion Criteria:

  • Previous or family history of Medullary Carcinoma of the Thyroid or multiple endocrine neoplasia syndrome.
  • Subjects with acute or chronic Pancreatitis

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01542242

Layout table for location information
Canada, British Columbia
Vancouver General Hospital - Diamond Center
Vancouver, British Columbia, Canada, V5Z 1M9
Sponsors and Collaborators
Vancouver General Hospital
Novo Nordisk A/S
Layout table for investigator information
Principal Investigator: Jason Kong, MD, FRCPC Vancouver General Hospital, University of British Columbia

Layout table for additonal information
Responsible Party: David E. Harris, MD, MD, Clinical Endocrinology Fellow, University of British Columbia, Vancouver General Hospital Identifier: NCT01542242     History of Changes
Other Study ID Numbers: PWS.VGH.UBC
First Posted: March 2, 2012    Key Record Dates
Last Update Posted: December 9, 2015
Last Verified: December 2015
Keywords provided by David E. Harris, MD, Vancouver General Hospital:
Diabetes Mellitus Type 2
Prader Willi Syndrome
Additional relevant MeSH terms:
Layout table for MeSH terms
Prader-Willi Syndrome
Diabetes Mellitus
Diabetes Mellitus, Type 2
Pathologic Processes
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Intellectual Disability
Neurobehavioral Manifestations
Neurologic Manifestations
Nervous System Diseases
Abnormalities, Multiple
Congenital Abnormalities
Chromosome Disorders
Genetic Diseases, Inborn
Nutrition Disorders
Hypoglycemic Agents
Physiological Effects of Drugs
Hormones, Hormone Substitutes, and Hormone Antagonists